DiagnosTear Ltd. is a start-up company developing the TeaRx™, a novel device to aid in diagnosing, monitoring and companion diagnostics of Dry Eye Syndrome. The TeaRx™ is intended to become a clinically valuable point-of-care test as well as a companion diagnostic test. Dry Eye Syndrome (DES) is a common disorder of the ocular surface in which the eye produces insufficient tears or tears with abnormal composition. It is one of the leading causes of patients’ visits to eye care practitioners in the United States. The TeaRx™ approach is to measure several tears’ components to achieve a rapid, simple, semi-quantitative analysis of the tear film. We believe that in order to effectively diagnose and treat DES, physicians must have an accurate multi-assays test for the detection and monitoring of the disease, in order to personalize therapy for DES patients and have the ability to determine the effectiveness of the selected therapy. The TeaRx™ performance was assessed in three clinical trials in the US. In the 2nd clinical trial the results demonstrated sensitivity of 86% and specificity of 87%. Based on the positive results of our clinical trials, the company submitted a pre-sub application to the FDA and getting ready for its regulatory trial on 2018.